‘A Watershed Moment’: GLP-1 Drug Succeeds in Late-Stage MASH Trial
Meeting Coverage > > AASLD-- First favorable stage III research study for a GLP-1 agonist in persistent liver illness
by Mike Bassett, Staff Writer, MedPage Today November 20, 2024
Semaglutide (Wegovy) enhanced liver fibrosis in clients with metabolic dysfunction-associated steatohepatitis (MASH) and resulted in higher rates of MASH resolution, an interim analysis of a stage III trial revealed.
In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist led to greater week-72 rates of steatohepatitis resolution without getting worse of liver fibrosis (63% vs 34% with placebo) and enhancement in liver fibrosis without in...